Rosen, Lauren (LA)

From: Trials < Trials@USPTO.GOV>

Sent: Wednesday, September 20, 2017 6:57 AM

To: Danek, Brenda (CH); Trials

Cc: #C-M PAR IPR ACTIONS - LW TEAM; ZortressAfinitorIPR@fchs.com

Subject: RE: Par v. Novartis, IPR2016-01479

Counsel,

Par is authorized to file, on or before September 22, 2017, the proposed one-page table containing citations to the record but no further argument.

Regards,

Andrew Kellogg, Supervisory Paralegal Patent Trial and Appeal Board USPTO

<u>andrew.kellogg@uspto.gov</u> Direct: 571-272-5366

From: brenda.danek@lw.com [mailto:brenda.danek@lw.com]

Sent: Thursday, September 14, 2017 10:13 AM

To: Trials < Trials@USPTO.GOV>

Cc: paripractions.lwteam@lw.com; ZortressAfinitorIPR@fchs.com

Subject: Par v. Novartis, IPR2016-01479

Dear Respected Board,

On September 5, 2017, Novartis filed a sur-reply to identify and respond to allegedly new arguments in Par's reply brief.

Par writes now to seek permission to file a one-page table it has prepared identifying where these allegedly new arguments appear in the Petition and/or the arguments in Novartis's response to which they respond. This table contains citations and no argument.

Par has conferred with Novartis and Novartis has indicated that it will oppose such a request. If the Board feels a teleconference would be helpful to discuss this request, Par and Novartis are available in the afternoon of Monday, September 18 or any time Tuesday, September 19.

Respectfully, Brenda Danek Counsel for Petitioner Par Pharmaceutical, Inc.

Brenda L. Danek

LATHAM & WATKINS LLP

330 North Wabash Avenue, Suite 2800 Chicago, IL 60611 Direct Dial: +1.312.876.7646 Fax: +1.312.993.9767

DOCKET A L A R M Par Pharm., Inc. Exhibit 1127 Par Pharm., Inc. v. Novartis AG Case IPR2016-01479

http://www.lw.com

This email may contain material that is confidential, privileged and/or attorney work product for the sole use of the intended recipient. Any review, disclosure, reliance or distribution by others or forwarding without express permission is strictly prohibited. If you are not the intended recipient, please contact the sender and delete all copies including any attachments.

Latham & Watkins LLP or any of its affiliates may monitor electronic communications sent or received by our networks in order to protect our business and verify compliance with our policies and relevant legal requirements.

Latham & Watkins LLP

